In Massachusetts, Audax Medical, Inc. has a worldwide license from Northeastern University for new nanotechnology of a self-assembling arginine-rich peptide to add to its current tissue regeneration platform. They plan to use this new nanotech for their medical applications and tissue regeneration. The newly developed nanostructures have antimicrobial properties, but unlike antibiotics which go after specific cellular activity, the nanoparticles aim specifically for the microorganisms’ cytoplasmic membrane which limits the inflammation and infection in surrounding tissue. Mark Johanson, Audax’s CEO, told PR Newswire, “We are excited to be collaborating with Northeastern’s team of world-class researchers. This technology fits perfectly with our company’s core biologics platform, while expanding potential clinical opportunities in the growing Wound Care and Anti-Infection markets.”
Latest article
Kiwi company turns kiwi waste into leather
In New Zealand, a startup called KiwiLeather Innovations is building a business converting rejected kiwifruit into a leather alternative.
According to Fresh Plaza, over...
UPSIDE Foods serves cultivated chicken at Indy 500 ahead of state ban
In Indiana, UPSIDE Foods served cultivated chicken sandwiches during the recent Indianapolis 500 as it called the state’s upcoming ban on such products “un-American.”...
Bee-free honey maker MeliBio acquired by FoodYoung Labs
In California, MeliBio, a pioneer in bee-free food, has been acquired by Switzerland-based foodtech FoodYoung Labs for an undisclosed sum.
MeliBio has earned global...